Abstract 2139P
Background
Long-term cancer survivors (LS), patients over 5 years free of disease, are a population on the rise due to oncological advances. Our aim is to explore QLACS in long-term cancer survival patients in Spain. As a secondary objective is to study their clinical and sociodemographic characteristics and their preference for social media or face-to-face meetings to obtain oncological information.
Methods
We carried out a transversal study in a sample of LS patients from several Spanish hospitals. They completed QLACS, FERREL, SPF12 and social media data. Different types of tumor were included. Psychometric properties of the QLACS were evaluated. Principal component analysis with Varimax rotation was applied to explore the dimensional structure. Pearson’s correlation (Pc) was used to study associations of QLACS with temporal variables. Student’s t test was used to study differences between them.
Results
N= 257, women=59,9 %, < 65 years=55%. Types Tumor: 33% breast, 27% colorectal, 8,9% urothelial, 7,4% other digestive tumors, 7% orl-lung. Factor analysis showed a 12-component solution accounts for 71.03 % of the variance, showing a similar comparable dimensional structure with QLACS. Alfa Cronbach=0,9. Appearance concern, distress over recurrence, pain, negative feelings and distress familiar are statistically higher in female (p<0,05). We found negative correlation between age and use of social networks for oncological information (Facebook: p = 0.01, Pc: -248; Twitter: p<0.04, Pc:- 200; Instagram: p <0.007, Pc: -259 except; Youtube: p = 0.17; Pc: -134). No differences by sex were observed in the use of social networks There were no differences by age in attending face-to-face meetings: p< 0.94, Pc: - 196. Breast cancer patients are more willing to attend face-to-face meetings to help other patients than those with colon cancer (p< 0.036).
Conclusions
QLACS is a valid and reliable instrument for measuring quality of life in long-term cancer survivors in Spain. Younger patients are more likely to use social media for oncology information. Older people tend to prefer face-to-face meetings. We found differences between men and women in different factors for measuring quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Cornide.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07